Conclusion
B. lactis CNCM 1-2494 can survive gastric transit in healthy adults after consumption of 250g Activia®
Activia Science Unveiled
Individual summaries of Activia’s strain survival studies to the gut and beyond
Can B. lactis CNCM 1-2494 survive gastric transit after Activia® consumption?
Berrada et al., 1991[1]
Study type
Randomised trial and simulated gastric emptying model
Intervention
Product 1, Activia (at least 10^7 CFU/g bifidobacterium) and product 2, another commercially available fermented milk (lower amount of bifidobacterium)
Study end points
A group: Survival of Bifidobacterium strains (Samples collected using a gastric tube immediately and 30, 60 and 90 minutes after ingestion; enumeration by plate counting). B group: Gastric emptying rate (detection of 99m-Tc-technetium-labelled solution ...
Population
10 healthy fasted adults (20-45 y/o) (Group A) and 12 healthy fasted adults (22-25 y/o) (Group B)
Length
A group: Samples collected at ingestion, 30, 60 and 90 minutes. B group: gastric emptying rate every 10 minutes, over 3 hours.
Key results
Significant difference
between the in vivo survival of the two bifidobacterium strains after 90 minutes of gastric transit, with bifidobacterium from Activia surviving in higher numbers
No significant difference
in gastric emptying between Activia and the comparator product
Can B. lactis CNCM I-2494 survive passage through the small intestine?
Pochart et al., 1992 [2]
Study type
Randomised, controlled, open study
Intervention
Daily consumption of either 400g servings of Activia®
Study end points
Plate counting from ileal perfusion to measure viable bifidobacteria
Control
monitored diet containing no bifidobacteria species
Population
6 healthy adults (18-30 y/o)
Length
8 hours
Key results
In the control group,
the ileal flow rate of viable bifidobacteria remained stable and low throughout the experiment
In the Activia® group,
a significant increase in the flow of bifidobacteria was observed and a large quantity of bifidobacteria was recovered from the terminal ileum
Conclusion
B. lactis CNCM I-2494 can reach the colon after consumption of Activia®
Can B. lactis survive intestinal transit in large quantities?
Duez et al., 2000[3]
Study type
Non-randomised, non-controlled, open study
Intervention
Daily consumption of 3 x 125g servings of Activia®
Study end points
Colony immunoblotting and cell counts to measure detection of Bifidobacteria in human faecal samples
Population
5 healthy women (20-48 y/o)
Length
7 days
Key results
No colonies of B. lactis CNCM I-2494
were detected in any of the faecal samples before ingestion of Activia®
After 7 days of Activia® consumption,
the population of B. lactis CNCM I-2494 in faecal samples was measurably high
Conclusion
B. lactis CNCM 1-2494 can survive the intestinal tract in large quantities following Activia® consumption
Can B. lactis survive passage through the human gastrointestinal (GI) tract?
Collado et al., 2006[4]
Study type
Non-randomised, non-controlled, open trial
Intervention
Daily consumption of 250ml servings of Activia® (n = 10)
Study end points
Various molecular techniques to detect bacterial species, including PCR and FISH in faecal samples; PCR to identify B.lactis CNCM I2494 profile
Control
daily consumption of 250ml servings of Activia® for 3 months prior to the study (n = 1, +ve control) or no product ingested (n = 1, -ve control)
Population
12 young healthy adults (25-40 y/o)
Length
4 weeks intervention plus 4 week follow up
Key results
Significant increase
of bifidobacteria in faeces observed during product consumption versus baseline
The number of bifidobacteria genus
The number of bifidobacteria genus in the +ve and –ve controls remained stable over the studied period. No B. lactis was detected in the –ve control
Conclusion
B.lactis CNCM 1-2494 successfully survives passage through the gastrointestinal tract following daily Activia® consumption over 4 weeks
Can B.lactis survive passage through the gastrointestinal (GI) tract?
Rochet et al., 2008[5]
Study type
Randomised, open, parallel study
Intervention
Daily consumption of either 3 x 125g servings of Activia® (n = 6) or 1g of freeze-dried powder of B. lactis CNCM I-2494 (n = 6)
Study end points
Colony immunoblotting, FISH and electrophoresis to detect specific bifidobacterium and microbiota in faecal samples
Population
12 healthy adults (24-46 y/o)
Length
7 days plus 10 day follow up period
Key results
B.lactis CNCM I-2494 detected
in the faeces of 5 out of 6 people in both groups at a sufficient level to demonstrate it survived passage through the gastrointestinal tract
Conclusion
B lactis CNCM I-2494 survives passage through the gastrointestinal tract following 3 x 125g servings of Activia® and 1g freeze-dried powder
References
[1] Berrada N et al. Bifidobacterium from fermented milks: Survival during gastric transit. Journal of Dairy Science, 1991;74:409-413.
[2] Pochart P et al. Survival of Bifidobacteria ingested via fermented milk during their passage through the human small intestine: an in vivo study using intestinal perfusion. American Journal of Clinical Nutrition, 1992; 55:78-80.
[3] Duez H et al. A colony immunoblotting method for quantitative detection of a Bifidobacterium animalis probiotic strain in human faeces. Journal of Applied Microbiology, 2000; 88:1019-27.
[4] Collado MC et al. Molecular detection of Bifidobacterium animalis DN-173 010 in human feces during fermented milk administration. Food Research International, 2006; 39: 530-535.
[5] Rochet V et al. Survival of Bifidobacterium animalis DN-173 010 in the fecal gut microbiota after administration in lyophilised form or in fermented product - A randomized study in healthy adults. Journal of Molecular Microbiology and Biotechnology, 2008; 14: 128-136
Explore more
This information is intended to provide health professionals with scientific and educational content on gut health and nutrition.
